Background. The effects of the endothelium-dependent vasodilator substance P (SP) on atherosclerotic human coronary arteries was studied.
nary arteries, as well as into the coronary arteries of the transplanted heart,37 have been examined. Thus far, the general conclusion has been that normal coronaries may preserve a vasodilator response to ACh2A but, in the presence of even mild disease25,6 or merely an increased number of risk factors for coronary artery disease,8 the vascular smooth muscle, muscarinic, constrictor response predominates, and the net result is vasoconstriction.
The neuropeptide substance P (SP) is an endothelium-dependent vasodilator9'10 without vasoconstrictor activity.'1 Upon infusion into the angiographically normal human coronary circulation, this agent elicits substantial epicardial dilatation and small increases in coronary flow. ' sions of the endothelium-dependent vasodilator substance P in humans.
Methods

Autoradiography
The localization of [125I]-SP binding sites was determined in atherosclerotic human coronary arteries using a protocol described by Charlton and Helke. 13 Human coronary artery segments were obtained from hearts of patients with ischemic heart disease that were removed at the time of cardiac transplantation. The arteries were dissected free and washed in sterile phosphate-buffered saline and then frozen at -196°C. The tissue was stored at -70C until use. Macroscopically normal segments of coronary arteries manifestly diseased at other points were mounted onto cryostat chucks using cardice in OCT embedding compound. Twenty-micrometer serial transverse sections were cut in a cryostat (Bright's) at -20°C and thaw-mounted onto gelatin-coated slides. Slidemounted sections were preincubated for 10 minutes at 22°C in 50 mM Tris buffer, pH 7.4, containing 0.02% bovine serum albumin, 40 /g/ml bacitracin, 100 KIU/ml aprotinin, and 2.5 mM EDTA (ethylenediaminetraacetic acid) to reduce levels of endogenous peptide. After preincubation, sections were washed for 6 minutes in the above buffer with EDTA replaced with 3 mM MnCl2 before being incubated for 75 minutes in buffer plus MnCl2 containing 50 pM [1251]-SP (specific activity, 2,200 Ci/mmol, New England Nuclear). Slide-mounted sections were then washed four times for 30 seconds in buffer at 4°C and dried in a stream of cold air. The degree of binding to nonspecific sites was established by incubating paired sections as above but in the presence of 10 ,uM unlabeled SP (Sigma). After drying, slide-mounted sections were apposed to Hyperfilm 3H (Amersham) for 4-12 days at 4°C before being processed for low-resolution autoradiographs.
High-resolution autoradiography. Ten-micrometer slide-mounted sections were postfixed by exposure to paraformaldehyde vapor (80°C for 2 hours) in an evacuated desiccator. Sections were then defatted by two Histoclear (National Diagnostics) washes and a series of aqueous ethanol (10-70%) washes followed by washing in glass-distilled water. Slides were then dipped individually into molten nuclear emulsion (Ilford K2, diluted 1:1 with 2% glycerol in glassdistilled water) and allowed to dry for several hours at room temperature. Slides were stored in lightproof boxes containing silica gel for up to 28 Angiograms of the seven patients with widespread coronary disease were analyzed for changes in vessel diameter at a smooth segment of a diseased vessel (see "Methods"). Figure 4 shows the coronary arteriogram of a typical patient with widespread coronary artery disease where SP-induced vasodilatation was demonstrated. The absolute coronary artery diameter at each dose of SP and after ISDN for each patient is shown in Figure 5 . Two patients showed no response to SP (dashed lines), and only one of these appeared to exhibit dilatation after ISDN. The dose-dependent increase in coronary artery diameter was just significant (p=0.04) when all seven patients were grouped together. Interdose comparison (by least significant difference) showed that maximal dilatation was produced at 5.6 pmol/min SP, producing 21.7+19.2% increase in coronary diameter. No significantly greater degree of dilatation was achieved with 2 mg intracoronary ISDN (27.0±+ 17.3% increase).
Group 2: response of discrete coronary stenoses. The responses of the six stenotic segments of the six patients studied are shown in Figures 6 and 7 . Figure  6 shows the data for the stenotic segment as well as the segment immediately proximal to the stenosis after the SP infusions in each of the individual patients. The average mean stenosis of the lesions in the segments analyzed as stenotic was 42% (range, 21-62%) under basal conditions. Figure 6 shows that only one stenotic segment appeared to dilate in response to SP (patient 2), achieving a 19% increase in diameter. One stenotic segment did not respond to SP but seemed to respond to ISDN, and in this vessel the adjacent, normal segment (patient 6) exhibited dose-dependent vasodilatation to SP. When the response above basal of all six proximal segments were 
Peripheral Hemodynamic Responses
Analysis of the change in heart rate and femoral artery pressure from the beginning to the end of each infusion in the group 1 patients showed no significant change in heart rate. The systolic and diastolic blood suggesting a specific failure of the endotheliumdependent response in that vessel segment. Analysis of six discrete stenotic lesions showed that only one dilated in response to SP and ISDN, one failed to dilate in response to SP but preserved ISDN-induced vasodilation, and the remainder were fixed. The doses of SP used were very comparable with a previous study in this department in which the response of coronary arteries that were angiographically normal throughout their length were studied. 12 In that group of patients, maximal dilatation was achieved with the dose of 11.2 pmol/min of SP, and in the study reported here the maximum effects on the normal segments of diseased vessels were seen at the dose of 5.6 pmol/min. The difference between these two doses is unlikely to be significant in a doublingdose protocol with an agent that is notorious for developing tachyphylaxis.11 The similarity of the two doses does, however, demonstrate that SP remains equipotent between normal segments of epicardial coronary arteries of patients with coronary atherosclerosis and angiographically normal coronary arteries. The degree of dilatation induced by SP in the normal segments of diseased vessels suggests that, in addition, SP remains an efficacious coronary vasodilator under these circumstances. The analysis of the peripheral hemodynamic effects shows that maximal epicardial coronary vasodilatation was achieved in the absence of identifiable systemic effects, and presumably the effects seen are a result of the direct action of the peptide on the coronary circulation.
The autoradiographic studies show that the luminal binding of SP is to the group of cells that line the vessel, which are interrupted focally, presumably by the atherosclerotic process. It is likely that this represents binding to endothelial cells. The studies demonstrate clearly the absence of SP binding to vascular smooth muscle cells and indicate the unlikelihood of confusing smooth muscle effects with the SP infusions.
Evidence that the vasodilatation induced by SP in this study was the direct result of endotheliumderived relaxing factor (EDRF) generation by the remaining endothelium in the diseased coronary vessels cannot, however, be more than circumstantial. Currently, the only EDRF-blocking agent that has been used in the human coronary circulation in vivo is methylene blue. However, this is a nonspecific agent, inhibiting guanylate cyclase directly16 as well as having action on the enzyme cyclooxygenase.17 SP has, however, been shown to be an endotheliumdependent vasodilator in several species9110 including humans,18 and experiments with endothelial cells grown in culture indicate that SP releases EDRF.19 SP has also been shown to release EDRF in a dose-dependent manner from porcine coronary artery segments.20 It has been shown that EDRF is in fact nitric oxide,21 which is synthesized from L-arginine. 22 Experiments with the agent NG-monomethyl-L-arginine (L-NMMA), which inhibits EDRF synthesis from L-arginine, have shown that SP-induced endothelium-dependent vasodilation is inhibited by L-NMMA in rabbit aorta,23 providing further evi dence that SP acts via release of EDRF. Similar experiments using human coronary rings have shown that SP-induced vasodilatation is abolished by treatment with L-NMMA. 24 There is, therefore, overwhelming evidence that SP-induced vasodilatation is dependent on EDRF release from endothelium.
Comparison of these results with previous studies in the literature might suggest that similar segments of coronary artery would produce a constrictor response when infused with ACh, whereas ACh dilated undiseased coronary vessels.23,576X8 These ACh results were interpreted in terms of a failure of endothelium at sites of early atherosclerosis (believed to be present but undetectable by angiography, a phenomenon previously documented25,26) to produce EDRF in response to ACh. If the smooth segments of the vessels of the patients reported here (who had severe three-vessel disease) were similarly affected by angiographically unidentifiable atherosclerosis, a potential difference between the responses to SP and those that might be predicted to occur with ACh appears to exist. The results reported here suggest that the segments of epicardial coronary artery analyzed (smooth segments distal to stenoses in patients with three-vessel disease and segments immediately proximal to flow-limiting stenoses) are still capable of producing an endothelium-dependent response. Pertinent to this comparison are the studies of flowinduced vasodilatation in the coronary circulation. The phenomenon of flow-induced vasodilatation has been examined in human coronary arteries that were angiographically normal or exhibited features of disease described as luminal irregularities. Flow-induced vasodilatation appears to be an endotheliumdependent response in the coronary circulation of dogs.27 Studies have shown that vessels with luminal irregularities do not sustain flow-induced vasodilator responses.28-30 One of these studies also demonstrated the same segments that were devoid of a flow-induced response were similarly devoid of a dilator response to infused acetylcholine.30 However, Cox et a129 did demonstrate that flow-induced vasodilatation was preserved in the normal segments of vessels that were diseased, albeit distal to the site of analysis.
Comparing like with like between studies is clearly very difficult. There are, unfortunately, a number of problems involved in performing a direct comparison study between acetylcholine and SP in the same patient (see "Limitations"). There will always be intrinsic differences between patients, and the very nature of atherosclerotic coronary artery disease is heterogeneous, ranging from vessels that appear angiographically normal to those with gross luminal irregularities and focal stenoses. What is clear, however, is that in patients who have angiographically widespread coronary artery disease at the segments analyzed in this study, which were smooth, there can be a preserved dilator response to the endothelium-dependent agent SP. Other studies suggest that unless a coronary artery is completely smooth throughout its length, it is unlikely to sustain a dilator response to acetylcholine. Vessels with luminal irregularities appear to lose the acetylcholine dilator response as well as the capacity to sustain flow-induced vasodilatation. What is described here is the preservation of a dilator response to substance P in smooth segments of diseased vessels, and this appears to contrast with some of the original observations of the effect of acetylcholine2,3 but gives s-upport to the observation of preserved flow-induced dilatation in normal segments of vessels with distal irregularities. 29 Human coronary artery dilator responses examined in vitro give some support to this suggested difference between acetylcholine and SP. In human coronary rings not affected by atherosclerosis, SP produces dose-dependent relaxation that is completely abolished by removal of the endothelium. 18 Human coronary rings from patients with atherosclerosis do not relax with ACh, whereas the same rings can show a small dilator response to SP. 18, 24, 31 It is tempting to speculate that there is a hierarchy of endothelial cell disruption with the development of coronary artery atherosclerosis. Perhaps EDRF synthetic capacity is preserved until late in the disease, but there is a hierarchical loss of agonistinduced release. For example, it is possible that acetylcholine responsiveness is lost early in the disease and that SP responsiveness is preserved until quite late, with other functions such as flow-induced release somewhere between these two effects. Such a hypothesis is pure speculation, and it is always possible that with downregulation of one response there may be relative upregulation of another.
Limitations
The in vivo observations using SP infusions reported here, and the suggestion that the angiographically smooth segments analyzed can still synthesize EDRF in response to SP, unfortunately, using our technology, cannot be directly compared with the responses of such vessels to ACh. Because all vessels, even those that are angiographically normal, will constrict to some dose or other of ACh,5 it is not possible to choose a single dilator dose of ACh for the purpose of comparative studies; therefore, the establishment of a clear absence of a dilator response to ACh demands the infusion of the full doseresponse curve of ACh up to and including the constrictor doses. If such a study were undertaken, which would contravene the radiation guidelines in the United Kingdom (see below), the acetylcholine dose-response curve would need to be performed before the SP infusions because the SP probably would produce a dilator response that would mask the ACh effect if it were to be seen. The constrictor doses as detailed above would need to be included, and in the group of patients studied here, this would produce ischemia requiring treatment that would then make a meaningful SP study impossible. For these reasons it seems that a meaningful, direct comparison within the same vessel segment cannot be made using graded intracoronary infusion studies of these two particular agents. Accordingly, these SP studies can only place the previously reported ACh studies into perspective by inferred comparison and cannot make any firm conclusions between the ACh and SP responses in diseased epicardial coronary arteries.
Repeated infusions of vehicle solution were not undertaken, thus reducing x-ray exposure in accordance with the new guidelines from the National Radiation Protection Board.32 However, our department has conducted a large number of studies in which the effects of up to five repeated control infusions and angiograms (using the same contrast media as used here) were examined, and no changes in coronary artery diameter were seen.'233 Furthermore, an SP dose-dependent increase in vessel diameter was seen in this group of patients after they had received a full diagnostic set of arteriograms, during which any contrast effect would probably have occurred.
The autoradiographic studies can only indicate that binding appears to be solely at the luminal surface of the vessels examined. Some functional significance can be inferred from the results of the intracoronary infusions, but clearly a direct causal link between the binding sites displayed and the vasodilatation seen in vivo cannot be made since deendothelialization studies in vivo and in vitro cannot be performed.
Conclusions
There is clearly a spectrum of response to SP in these diseased vessels. Two segments (one normal and one stenosed) did not dilate in response to SP but preserved a normal response to ISDN. These two segments, therefore, did have some degree of endothelial cell dysfunction such as a defect of the receptor, the transduction system, or of the EDRF synthetic capacity of those cells. However, the results of the angiographically normal segments of diseased vessels indicate that most of those segments are still capable of producing EDRF in amounts great enough to cause relaxation of the neighboring smooth muscle cells. Analysis of stenotic segments showed that one out of six such stenoses also dilated in response to SP. These results suggest that there may be a loss of the response to SP, which itself might suggest some degree of endothelial cell dysfunction, but that this appears to be only at sites of severe disease.
